Resolution Therapeutics has extended its inflammatory and fibrotic disease pipeline with its in vivo regenerative macrophage therapy (RMT). The announcement comes with Resolution executing Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering… Read More
The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Amir Hefni, CEO of Resolution Therapeutics. Resolution specialises in developing therapies for inflammatory and fibrotic diseases and is currently progressing a treatment for end-stage liver… Read More
Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases. GPR68, or OGR1,… Read More
Biotechnology company Calluna Pharma has completed a Phase I clinical study for its lead product candidate targeting inflammatory and fibrotic diseases. The company’s lead candidate, CAL101, was shown to have a favorable safety, pharmacokinetic (PK) and immunogenicity profile in the Phase I study. CAL101 is… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on skin conditions, with positive updates on hidradenitis… Read More
News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. The top stories: Dual-action treatment… Read More
AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and… Read More
Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. … Read More
Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, has shared topline monotherapy data from the biliary tract cancer (BTC) module of the RXC004 PORCUPINE2 Phase II clinical trial programme. RXC004 is an… Read More
